# Efficacy and Safety of Camrelizumab for Injection, Apatinib Mesylate and Tegio for First-line Refractory Patients With Advanced Gastric Cancer

> **NCT04345783** · PHASE2 · UNKNOWN · sponsor: **Beijing Friendship Hospital** · enrollment: 30 (actual)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Camrelizumab for injection, apatinib mesylate and tegio

## Key facts

- **NCT ID:** NCT04345783
- **Lead sponsor:** Beijing Friendship Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-01-01
- **Primary completion:** 2021-12-31
- **Final completion:** 2022-06-30
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2020-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04345783

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04345783, "Efficacy and Safety of Camrelizumab for Injection, Apatinib Mesylate and Tegio for First-line Refractory Patients With Advanced Gastric Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04345783. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*